These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2114029)

  • 1. [A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].
    Agounitestane D; Chiheb M; Khaled S; Ait Khaled N; Boulahbal F; Chaulet P
    Rev Mal Respir; 1990; 7(3):209-13. PubMed ID: 2114029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].
    Bellabas M; Khaled S; Khaled NA; Boulahbal F; Chaulet P
    Rev Mal Respir; 1989; 6(1):59-64. PubMed ID: 2648511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
    Teo SK
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months].
    Mazouni L; Tazir M; Boulahbal F; Chaulet P
    Rev Mal Respir; 1985; 2(4):209-14. PubMed ID: 3937189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India.
    Paramasivan CN; Chandrasekaran V; Santha T; Sudarsanam NM; Prabhakar R
    Tuber Lung Dis; 1993 Feb; 74(1):23-7. PubMed ID: 8495016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis.
    Wolde K; Lema E; Roscigno G; Abdi A
    Ethiop Med J; 1992 Apr; 30(2):63-8. PubMed ID: 1345030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
    Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
    Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of 3 6-month chemotherapy regimes in pulmonary tuberculosis in routine practice in Algiers. 18th-month results].
    Chaulet P; Boulahbal F; Ait Khaled N; El Awadi Z; Tazir M
    Rev Fr Mal Respir; 1983; 11(5):667-76. PubMed ID: 6658153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.
    Moulding TS; Le HQ; Rikleen D; Davidson P
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):743-8. PubMed ID: 15182145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1988 May; 137(5):1147-50. PubMed ID: 2904237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
    Nowak D; Radenbach D; Magnussen H
    Pneumologie; 1990 Feb; 44 Suppl 1():497-8. PubMed ID: 2114634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
    Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
    Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.